We are delighted to announce that our portfolio company, Linnaeus Therapeutics, Inc., has closed a $12 million series B financing led by Kairos Ventures with participation by the Penn Medicine Co-Investment Fund at the University of Pennsylvania. Linnaeus is a biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics.

Linnaeus Therapeutics, Inc.

“We are thrilled with the progress Linnaeus has made in the twelve months since the closing of our Series A round. With the Series B investment closed we now look forward to advancing LNS8801 into our phase 1/2 clinical studies that should commence in the coming weeks.” – Patrick Mooney, M.D., Chief Executive Officer of Linnaeus

Linnaeus intends to use the proceeds from the financing to conduct its phase 1/2 clinical trial of its lead compound, LNS8801, in patients with advanced cancer.

“We are thrilled with the progress Linnaeus has made in the twelve months since the closing of our Series A round,” said Patrick Mooney, M.D., chief executive officer of Linnaeus. “With the Series B investment closed we now look forward to advancing LNS8801 into our phase 1/2 clinical studies that should commence in the coming weeks.”

We are excited about our continued investment in Linnaeus and pleased to have them as part of the extended Kairos Ventures family!